Lung cancer, comorbidities, and medication: the infernal trio
Hélène Pluchart, Sébastien Chanoine, Denis Moro-Sibilot, Christos Chouaid, Gil Frey, Julie Villa, Bruno Degano, Matteo Giaj Levra, Pierrick Bedouch, Anne-Claire Toffart · 2024
Read Lung cancer, comorbidities, and medication: the infernal trio by Hélène Pluchart, Sébastien Chanoine, Denis Moro-Sibilot, Christos Chouaid, Gil Frey, Julie Villa, Bruno Degano, Matteo Giaj Levra, Pierrick Bedouch, Anne-Claire Toffart (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10916800.txt.
Description
Helene Pluchart and co-authors published a review, with the head dated 2023, on the tangled links among lung cancer, other diseases, and medications. Most lung cancer patients are older smokers, so age and lifestyle diseases are common alongside the cancer. Those diseases bring their own drugs, sometimes many at once. Evidence tying the three together keeps growing.
Other diseases and their treatments can shift when cancer is found and which strategy fits. Cancer therapy, in turn, can worsen kidney failure, lung inflammation, or hormone gland problems. The review sorts how picked comorbidities change cancer presentation and force treatment changes. It also covers how each side's drugs affect the other.
Catalog record
| CREATOR | Hélène Pluchart, Sébastien Chanoine, Denis Moro-Sibilot, Christos Chouaid, Gil Frey, Julie Villa, Bruno Degano, Matteo Giaj Levra, Pierrick Bedouch, Anne-Claire Toffart |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 38 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |